Skip to content
Menu

Tango Therapeutics, Inc. TNGX

Full chart Compare
Set alert

Price alert · TNGX

All alert types
22.11 USD -2.06 (-8.52%)

Regular-session close

23.15 +1.04 +4.72%

After hours · Nov 17, 6:56 PM ET

22.05 Day range 24.32
7.69 52-week range 34.39
YTD
+149.55%
1 year
+177.07%
Market cap
3.75B
EPS (ttm)
-1.38
Shares out
169.46M
Forward P/E
-12.30
YTD return
+149.55%
1-year return
+177.07%
50-day average
23.56
200-day average
22.96
Enterprise value
3.15B
Price / book
3.82
Volume
2.06M
Avg volume
3.42M
Open
24.08
Previous close
24.17
Day's range
22.05 – 24.32
52-week range
7.69 – 34.39
Beta
1.22
Analysts
Strong Buy
Price target
47.00 (+112.6%)
Earnings date
Mar 4, 2027

5D +4.07 (+18.99%)

222426MonTueWedThuFri25.50

Key statistics

Free cash flow
-80.18M
Total cash
977.50M
Total debt
31.18M
Return on equity
-36.48%
Short % of float
28.83%

Fundamental scorecard

4 of 25 checks passed on TNGX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TNGX Revenue — quarterly 0
TNGX Net income — quarterly -68.39M
TNGX EPS — quarterly -0.39

Earnings

TNGX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 4, 2027Dec 30, 2026-0.39———
Nov 9, 2026Sep 30, 2026-0.35297-0.39-0.04-10.49%
Aug 10, 2026Jun 30, 2026-0.31722-0.37-0.05-16.64%
May 13, 2026Mar 31, 2026-0.3137-0.32-0.01-2.01%
Mar 5, 2026Dec 31, 2025-0.31-0.29+0.02+6.45%
Nov 4, 2025Sep 30, 20250.010.13+0.12+1,200.00%

Upgrades / downgrades

TNGX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 10, 2026JP MorganmainOverweightOverweight
Nov 10, 2026WedbushmainOutperformOutperform
Nov 10, 2026HC Wainwright & Co.mainBuyBuy
Oct 29, 2026HC Wainwright & Co.reitBuyBuy
Oct 16, 2026William Blairinit—Outperform
Aug 18, 2026HC Wainwright & Co.mainBuyBuy

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
tangotx.com

News

Your note

Sign in to keep a note on TNGX — it syncs with the Stock Master app.

Insider holders

TNGX insider holders
InsiderRelationLatest transactionDateShares held
BARRY DOUGLASGeneral CounselSaleFeb 4, 202566,014
BECKMAN DANIELLAChief Financial OfficerSaleFeb 2, 2026184,297
CRYSTAL ADAM SOfficerSaleNov 10, 2026115,743
GALL MATTHEWChief Financial OfficerStock Award(Grant)Apr 30, 202640,000
KETCHUM JOHN BDirectorStock Award(Grant)Jun 4, 202624,937
NEWCOMB JESSICAOfficerSaleNov 1, 202652,090

Institution ownership

TNGX institution ownership
Holder% heldSharesValueReported
RTW Investments LP8.29%14,048,477310.61MSep 29, 2026
FMR, LLC7.76%13,146,123290.66MSep 29, 2026
Blackrock Inc.7.76%13,143,069290.59MSep 29, 2026
Goldman Sachs Group Inc6.73%11,412,008252.32MSep 29, 2026
Boxer Capital Management, LLC6.21%10,526,219232.73MSep 29, 2026
State Street Corporation4.32%7,315,401161.74MSep 29, 2026

Fund ownership

TNGX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.59%4,395,73297.19MJun 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.40%4,065,30589.88MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.15%3,649,64480.69MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.66%2,818,15862.31MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio1.66%2,816,26262.27MSep 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.91%1,546,02734.18MJun 29, 2026